{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:08:09Z","timestamp":1783944489222,"version":"3.55.0"},"reference-count":19,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/internalmedicine.52.8496","type":"journal-article","created":{"date-parts":[[2013,3,31]],"date-time":"2013-03-31T22:38:59Z","timestamp":1364769539000},"page":"781-785","source":"Crossref","is-referenced-by-count":5,"title":["Surgically Proven Normocalcemic Primary Hyperparathyroidism: Speculation of the Possible Role of Estrogen in the Etiology of this Disease in Premenopausal Women"],"prefix":"10.2169","volume":"52","author":[{"given":"Seigo","family":"Tachibana","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Yamashita Thyroid and Parathyroid Clinic, Japan"},{"name":"Department of Endocrinology and Diabetes Medicine, Fukuoka University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yamashita Thyroid and Parathyroid Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yamashita Thyroid and Parathyroid Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Yanase","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Medicine, Fukuoka University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yamashita Thyroid and Parathyroid Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Silverberg SJ. Natural history of primary hyperparathyroidism. Endocrinol Metab Clin North Am 29: 451-464, 2000.","DOI":"10.1016\/S0889-8529(05)70145-6"},{"key":"2","unstructured":"2. Palmer M, Jakobsson S, Akerstrom G, Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Invest 18: 39-46, 1988."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Monchik JM. Normocalcemic hyperparathyroidism. Surgery 118: 917-923, 1995.","DOI":"10.1016\/S0039-6060(05)80094-7"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Monchik JM, Gorgun E. Normocalcemic hyperparathyroidism in patients with osteoporosis. Surgery 136: 1242-1246, 2004.","DOI":"10.1016\/j.surg.2004.06.052"},{"key":"5","unstructured":"5. Silverberg SJ, Bilezikian JP. \"Incipient\" primary hyperparathyroidism: a \"forme fruste\" of an old disease. J Clin Endocrinol Metab 88: 5348-5352, 2003."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 54: 106-109, 2010.","DOI":"10.1590\/S0004-27302010000200004"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Carneiro-Pla D, Solorzano C. A summary of the new phenomenon of normocalcemic hyperparathyroidism and appropriate management. Curr Opin Oncol 24: 42-45, 2012.","DOI":"10.1097\/CCO.0b013e32834c2fb9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 88: 1174-1178, 2003.","DOI":"10.1210\/jc.2002-020667"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Manickam B, Washington T, Villagrana NE, Benjamin A, Kukreja S, Barengolts E. Determinants of circulating 25-hydroxyvitamin d and bone mineral density in young physicians. Endocr Pract 18: 219-226, 2012.","DOI":"10.4158\/EP11269.OR"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341: 1249-1255, 1999.","DOI":"10.1056\/NEJM199910213411701"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93: 3462-3470, 2008.","DOI":"10.1210\/jc.2007-1215"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 57: 385-409, 2002.","DOI":"10.1210\/rp.57.1.385"},{"key":"13","unstructured":"13. Muneyyirci-Delale O, Nacharaju VL, Dalloul M, Altura BM, Altura BT. Serum ionized magnesium and calcium in women after menopause: inverse relation of estrogen with ionized magnesium. Fertil Steril 71: 869-872, 1999."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cosman F, Shen V, Xie F, Seibel M, Ratcliffe A, Lindsay R. Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med 118: 337-343, 1993.","DOI":"10.7326\/0003-4819-118-5-199303010-00003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gallagher JC, Nordin BE. Treatment with oestrogens of primary hyperparathyroidism in post-menopausal women. Lancet 1: 503-507, 1972.","DOI":"10.1016\/S0140-6736(72)90173-0"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Marcus R, Madvig P, Crim M, Pont A, Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 100: 633-640, 1984.","DOI":"10.7326\/0003-4819-100-5-633"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. McDermott MT, Perloff JJ, Kidd GS. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Miner Res 9: 509-514, 1994.","DOI":"10.1002\/jbmr.5650090410"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Selby PL, Peacock M. Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N Engl J Med 314: 1481-1485, 1986.","DOI":"10.1056\/NEJM198606053142304"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Reid IR. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med 125: 360-368, 1996.","DOI":"10.7326\/0003-4819-125-5-199609010-00002"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/7\/52_52.8496\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:48:17Z","timestamp":1621446497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/7\/52_52.8496\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.52.8496","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}